Lumento Therapeutics selected as Hello Tomorrow Global Challenge Finalist
January 16, 2020
We are very excited to announce that from the 5000+ start-ups that applied to Hello Tomorrow, Lumento Therapeutics has been selected as a Global Challenge Finalist in the Drug Discovery Track! We are looking forward to the event and pitching our innovation on the main stage for the jury and the 400+ investors and stakeholders.
December 13, 2019
We are pleased to announce that today the Review Board of Pharma Portal has positively reviewed our drug development strategy. We will be moving forward with our development programs with their continued support and expertise.
Lumento Therapeutics receives the NWO Take Off grant
December 9, 2019
The co-application of Lumento Therapeutics with the University of Groningen for the NWO Take Off grant was successful! With this funding, we can perform a feasibility study of our business plan and move one step closer to bringing our innovative technology to patients in need.
Lumento progresses to secound round of EIT Jumpstarter competition
September 4, 2019
Our team has been selected for the second round of the EIT Jumpstarter competition. We are honoured and we look forward to participating in the 40-hour Local Joint Training program this fall!
ERC Proof of Concept grant received
August 1, 2019
We are very happy to announce that our co-application with the University of Groningen for the European Research Council's Proof of Concept grant was approved. With this funding, we can continue our R&D program and develop a successful business model for Lumento Therapeutics to bring light-activated cancer therapy to patients.
Lumento selected for the EIT Health Jumpstarter competition
March 26, 2019
We are excited to join the EIT Health network as we participate in the Jumpstarter competition and the upcoming bootcamp with world-leading experts to improve our pitch and business plan.
Lumento joins VentureLab North!
February 1, 2019
The team of Lumento Therapeutics is excited to announce that we will join the Health specialization track of VentureLab North. During this one year business development programme, we will receive business training and coaching from experienced entrepreneurs.
In Vitro PoC Published
October 4, 2018
An article by our co-founders Mickel Hansen and Ben Feringa describing in vitro proof of concept with local light-activation of an anti-cancer drug was recently published in the Journal of the American Chemical Society. To read more, click the link below.